Benefit-risk assessment of sirolimus in renal transplantation.
about
Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney DiseaseHigh-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease modelBloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants.Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant PatientsMechanisms of diabetes mellitus induced with FK506 in SD rats models.Surgical biology for the clinician: vascular effects of immunosuppressionSirolimus is associated with new-onset diabetes in kidney transplant recipients.Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial.The food additive vanillic acid controls transgene expression in mammalian cells and miceImmunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity.Alleviating neurodegeneration in Drosophila models of PolyQ diseases.An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice.The role and value of sirolimus administration in kidney and liver transplantation.Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.Sirolimus-associated infertility: case report and literature review of possible mechanisms.Kidney transplantation: current issues and future prospects.Transporter-mediated uptake into cellular compartments.Considerations in sirolimus use in the early and late post-transplant periods.Everolimus: preventing organ rejection in adult kidney transplant recipients.An evaluation of sirolimus in renal transplantation.What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?The antiaging activity and cerebral protection of rapamycin at micro-doses.A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation.Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons.The use of everolimus in renal-transplant patientsTacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.Evidence of the immunomodulatory role of dual PI3K/mTOR inhibitors in transplantation: an experimental study in mice.Kinetic nomograms assist individualization of drug regimens.Rapamycin Nano-Micelle Ophthalmic Solution Reduces Corneal Allograft Rejection by Potentiating Myeloid-Derived Suppressor Cells' Function
P2860
Q27320627-5B766F03-7EDE-4A8E-A718-D2FD44D1CF12Q27323092-4E77615E-62D1-49D2-B672-E02FE637D536Q33253253-714BFC9D-AB74-4718-B5BD-37C1A41D8F0EQ33432698-661C1957-0C5D-4858-997E-87FEEA51ED73Q33513711-07F83B06-2C5B-484B-A912-3C85877A0C1BQ33604754-4542791A-D31A-41FE-953B-E7850958E25BQ34767143-6071C255-4BD8-4396-8F88-4FBA3B1F0AC1Q35706983-7C29C3F6-AAB5-46BE-A821-85215C6B903CQ35823680-ABC8BFA3-F9E8-41A9-BA07-666FA6D9F564Q35827879-BD771FEB-76B0-4984-9BEA-6B0DEF0D9DF3Q36003663-092FECDD-0BF1-4B65-BB4E-DD36B6AFBB97Q36328854-70C236E6-0D70-47A3-8826-48C920787F40Q36652031-62FB1B55-E826-4D45-A353-D35D5D2E6AA3Q36769277-012F9D75-EACA-4110-AA66-22439CBD36E7Q36874564-4EF74A74-973F-4049-B688-7852B2870D7EQ36936424-06B99B4C-A6C3-4A51-A54D-EA33EA380AC7Q36938148-DD12B599-3E38-4454-8A45-44E23349CABEQ36985076-9AA8A27B-B266-4E48-A616-364B51F32B2FQ37517602-AC461FDD-F949-4599-9216-17AB09369988Q37992135-B6A357E4-9BBE-41B3-96A6-88D32B791562Q38038696-9BD3AEAF-0C9C-44CD-8632-412194519E49Q38161821-40205CB7-2F15-4EC0-A475-5263D1C52B1FQ38946734-E7FB833F-4005-423E-9D9B-8CEA59358917Q39024541-93338C74-FA19-4C97-9B1A-F344EE475461Q39820135-B03CC403-2CE1-4486-97B1-31655AB87407Q41859603-4E48F32C-0827-4B41-950A-5C50B9949E79Q46936587-8217850E-69A6-42E4-AA4C-11C364DF7CF7Q48097984-2F36DA23-42BA-47C8-B491-649592316E5EQ51497219-A3705F6F-B92A-479C-9D9A-9E970369E244Q57817480-7EDEB3FA-82B9-4D77-8AC3-22604E321ACE
P2860
Benefit-risk assessment of sirolimus in renal transplantation.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Benefit-risk assessment of sirolimus in renal transplantation.
@ast
Benefit-risk assessment of sirolimus in renal transplantation.
@en
type
label
Benefit-risk assessment of sirolimus in renal transplantation.
@ast
Benefit-risk assessment of sirolimus in renal transplantation.
@en
prefLabel
Benefit-risk assessment of sirolimus in renal transplantation.
@ast
Benefit-risk assessment of sirolimus in renal transplantation.
@en
P1433
P1476
Benefit-risk assessment of sirolimus in renal transplantation.
@en
P2093
Dirk R J Kuypers
P304
P356
10.2165/00002018-200528020-00006
P577
2005-01-01T00:00:00Z
P6179
1036892589